Courtney Flaherty

Megan Melody, MD, discusses her journey as an oncologist and the importance of mentorship and a supportive work environment to empower women in the field.

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.

Brandon G. Smaglo, MD, FACP, discusses upfront treatment considerations for patients with metastatic pancreatic cancer.

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

China’s NMPA has granted priority review to an NDA for neoadjuvant ipilimumab injection plus sintilimab in MSI-H or dMMR colon cancer.

Andrew Kuykendall, MD, discusses the importance of a nuanced, multidisciplinary approach to expedite the diagnosis of indolent systemic mastocytosis.

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

The FDA has granted priority review to the sBLA for perioperative pembrolizumab plus adjuvant radiotherapy in resectable locally advanced HNSCC.

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Christopher P. Fox, MBChB(Hons), PhD, FRCP, FRCPath, discusses the ongoing evaluation of duvelisib in nodal T-cell lymphoma.

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

Patients with systemic mastocytosis experienced superior OS and DOT outcomes with first- and later-line avapritinib vs midostaurin and BAT, respectively.

Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

OS outcomes with lenvatinib plus pembrolizumab were prolonged in patients with PPP2R1A-mutated vs wild-type high-risk endometrial cancer.

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

Treatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.